Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Shafique Virani Biography and Net Worth

Chief Corporate Development Officer of Recursion Pharmaceuticals

Shafique Virani, M.D., has served as our Chief Corporate Development Officer since March 2020. He also served as our interim Chief Medical Officer from June 2022 to June 2023. Prior to joining us, he was Chief Executive Officer of Navire Pharma and CoA Therapeutics (each a subsidiary of BridgeBio Pharma, Inc.) from September 2017 to December 2019 and June 2018 to December 2019, respectively. He also served as Chief Executive Officer in Residence of BioBridge LLC from June 2017 to December 2019. Prior to BridgeBio, he assumed a 13-year long tenure at Genentech/Roche from January 2004 to June 2017 as Vice President and Global Head of Neuroscience, ophthalmology and rare disease partnering where he helped build a portfolio of medicines including Risdiplam for spinal muscular atrophy, Enspryng for neuromyelitis optica spectrum disorder and several therapeutics in the mid-late stage clinical pipeline via licensing and acquisitions. Dr. Virani trained as a neurosurgeon in Cambridge, UK and Boston and received his M.D. from the University of Nottingham.

What is Shafique Virani's net worth?: The estimated net worth of Shafique Virani is at least $1.11 million as of January 16th, 2024. Dr. Virani owns 136,748 shares of Recursion Pharmaceuticals stock worth more than $1,110,394 as of April 27th. This net worth estimate does not reflect any other investments that Dr. Virani may own. Learn More about Shafique Virani's net worth.
How do I contact Shafique Virani?: The corporate mailing address for Dr. Virani and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Shafique Virani's contact information.
Has Shafique Virani been buying or selling shares of Recursion Pharmaceuticals?: Shafique Virani has not been actively trading shares of Recursion Pharmaceuticals during the last ninety days. Most recently, Shafique Virani sold 18,000 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $10.93, for a transaction totalling $196,740.00. Following the completion of the sale, the insider now directly owns 136,748 shares of the company's stock, valued at $1,494,655.64. Learn More on Shafique Virani's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Tina Larson (COO), Dean Li (Director), Michael Secora (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 70 times. They sold a total of 1,443,105 shares worth more than $13,646,266.83. The most recent insider tranaction occured on April, 17th when CFO Michael Secora sold 23,124 shares worth more than $175,279.92. Insiders at Recursion Pharmaceuticals own 20.0% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 4/17/2024.

Shafique Virani Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2024	Sell	18,000	$10.93	$196,740.00	136,748
12/15/2023	Sell	18,000	$9.60	$172,800.00	136,748
11/15/2023	Sell	18,000	$6.51	$117,180.00	140,351
10/16/2023	Sell	18,000	$6.30	$113,400.00	140,351
9/15/2023	Sell	18,000	$8.66	$155,880.00	140,351
8/15/2023	Sell	18,000	$9.25	$166,500.00	140,351
7/26/2023	Sell	20,000	$14.41	$288,200.00	143,954
7/17/2023	Sell	30,000	$11.72	$351,600.00	143,954
6/1/2023	Sell	25,000	$8.58	$214,500.00	161,819
2/15/2023	Sell	7,486	$8.33	$62,358.38	189,846
1/17/2023	Sell	10,000	$9.16	$91,600.00	73,160
12/15/2022	Sell	10,000	$8.85	$88,500.00	78,160
11/15/2022	Sell	10,000	$12.31	$123,100.00	83,160
10/14/2022	Sell	10,000	$10.92	$109,200.00	88,773
9/15/2022	Sell	10,000	$13.36	$133,600.00	93,773
8/16/2022	Sell	30,000	$12.61	$378,300.00	98,773

Shafique Virani Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $8.12

$7.68

$8.14

50 Day Range

MA: $10.37

$7.35

$15.52

2 Week Range

Now: $8.12

$4.54

$16.75

Volume

4,394,004 shs

Average Volume

4,187,155 shs

Market Capitalization

$1.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76